| |
| HEALTHCARE |
U.N. Environment Programme Urged to Protect Nature and Humankind from Electromagnetic Fields (EMF)
July 22, 2019
The Advisors to the International EMF Scientist Appeal, representing 248 scientists from 42 nations, have resubmitted The Appeal to the United Nations Environment Programme (UNEP) Executive Director, Inger Andersen, requesting the UNEP reassess the potential biological impacts of next generation 4G and 5G telecommunication technologies to plants, animals and humans. There is particular urgency at this time as new antennas will be densely located"...
Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease
July 22, 2019
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the VISIBLE 2 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of the gut-selective biologic vedolizumab as maintenance therapy in adult patients with moderately to severely active Crohns disease (CD) who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous (IV) therapy at weeks 0 and 2.1 In evaluating the primary endpoint of the trial, a statistically significant proportion of patients receiving vedolizumab SC achieved clinical remission** at week 52 compared to placebo. Patients received vedolizumab SC beginning at week 6 and every 2 weeks up to week 50.1 Adverse events were consistent with the known safety profile of vedolizumab IV, and no new signals were identified. “Meeting......
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease
July 20, 2019
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral"...
Novartis raises full-year targets, aims to settle U.S. lawsuit
July 18, 2019
ZURICH (Reuters) - Novartis (NOVN.S) boss Vas Narasimhan raised full-year targets on Thursday and announced that $700 million has been set aside in the hope of settling a decade-old lawsuit alleging that the Swiss drugmaker bribed U.S. doctors. Shares in the company rose about 5% to their highest since 2015, buoyed by second-quarter results, earnings guidance and the prospect of avoiding trial in a case that began in 2011 as a whistleblower lawsuit"...
AHF to WHO: Ebola Response, Too Little, Too Late!
July 18, 2019
The World Health Organization (WHO) has finally declared a Public Health Emergency of International Concern (PHEIC) in the Democratic Republic of the Congo on July 17 as a long overdue acknowledgement that the current Ebola outbreak remains uncontained and still poses a significant threat to global health"...
Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics
July 18, 2019
Boehringer Ingelheim and Bridge Biotherapeutics Inc. today announced that they are entering into a new collaboration and license agreement with the goal of developing Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 for patients with fibrosing interstitial lung diseases, including IPF. BBT-877 is currently in Phase I clinical studies and is anticipated to enter Phase II testing within the next 12 months. Both companies will initially focus"...
WHO Regional Director in Iraq to reinforce WHO support as country enters transition to development phase
July 16, 2019
Baghdad, 15 July 2019--- Regional Director for the World Health Organization’s Eastern Mediterranean Dr. Ahmed Al Mandhari arrives to Iraq today to mark a major strategic shift in WHO’s work in the country. For many years, WHO’s priority work in Iraq was focused on responding to urgent health needs as a result to the ongoing crisis. This year, WHO’s focus will move from pure emergency response operations to both emergency"...
AHF: Clock Is Ticking, WHO – Act Now on Ebola!
July 16, 2019
With the first reported case of Ebola emerging this week in Goma, a populous city in the eastern Democratic Republic of the Congo (DRC) next to the Rwandan city of Gisenyi, medical care providers and public health advocates from AIDS Healthcare Foundation (AHF) are speaking out loudly—declaring"...
ResMed Inc. Completes $500M Private Placement Debt Offering
July 16, 2019
ResMed Inc. (NYSE: RMD, ASX: RMD) announced today the successful pricing and closing of a private placement offering of $250,000,000 principal amount 3.24% senior notes due July 10, 2026, and $250,000,000 principal amount 3.45% senior notes due July 10, 2029. Net proceeds from the offering will be approximately $498 million, after deducting estimated fees and expenses related to the offering. The net proceeds will be used to pay down current borrowings"...
CosmeSurge, the pioneer in aesthetic services, launches its 15th clinic
July 16, 2019
CosmeSurge, one of the region’s most trusted brands for cosmetic and aesthetic procedures, has launched its 15th centre in the UAE and Oman. Located on the second floor of Bareen International Hospital in Mohammed Bin Zayed City, Abu Dhabi, the centre will provide innovative, high quality aesthetic and cosmetic dermatology and plastic surgery services for which the brand is renowned. NMC Health’s Chief Operating Officer Michael Davis"...
|
|
|
|
|